RIDGEFIELD, Conn., Feb. 19 Boehringer IngelheimPharmaceuticals, Inc. today announced that it has received the prestigiouscertification from the National Committee for Quality Assurance (NCQA) for itseducational resources and programs related to chronic obstructive pulmonarydisease (COPD). A chronic illness that may result in severe morbidity, COPD,which includes chronic bronchitis, emphysema, or both, is the fourth-leadingcause of death in the United States. (1)
To address this problem and inform the public about COPD, BoehringerIngelheim has and continues to raise awareness about this serious diseasethrough education and initiatives for patients, healthcare practitioners, andhealth plans. As a result of these efforts, the company has become one ofjust a few recognized by the NCQA for their efforts.
"This recognition is an important milestone that highlights our commitmentto making a difference in the management of chronic diseases," said ChrisBarrett, Senior Vice President, Managed Markets. "Boehringer Ingelheim isdedicated to helping to improve the lives of people living with seriouschronic diseases such as COPD, and we continue to collaborate with the NCQA aswe develop health management programs in other important areas, such as strokeand prevention of secondary stroke."
Margaret E. O'Kane, President of NCQA agrees. "Earning NCQA DiseaseManagement Certification indicates that a disease management (DM) programexcels in the specific area in which it was reviewed, either program design,patient outreach, or DM systems. It's an accomplishment of which to be veryproud."
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, isthe largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield,CT) and a member of the Boehringer Ingelheim group of companies. TheBoehringer Ingelheim group is one of the world's 20 leading pharmaceuticalcompanies. Headquartered in Ingelheim, Germany, it operates globally with 137affiliates in 47 countries and approximately 38,400 employees. Since it wasfounded in 1885, the family-owned company has been committed to researching,developing, manufacturing and marketing novel products of high therapeuticvalue for human and veterinary medicine.For more information, please visit http://us.boehringer-ingelheim.com. (1.) National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2007 chart book on cardiovascular, lung, and blood diseases. [NHLBI2007/P9/Chart 2-8] June 2007. U.S. Department of Health and Human Services, National Institutes of Health; 2007. www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed December 12, 2007.
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.